On December 1, 2004, Johnson & Johnson Pharmaceutical Research & Development announced discontinuation of the current clinical development program for its controlled-release formulation of topiramate in obesity and type 2 diabetes.
Advances in the Long-Term Treatment of Obesity
Article first published online: 6 SEP 2012
2004 North American Association for the Study of Obesity (NAASO)
Special Issue: Advances in the Long-Term Treatment of Obesity
Volume 12, Issue S12, pages 149S–150S, December 2004
How to Cite
Klein, S. (2004), Advances in the Long-Term Treatment of Obesity. Obesity Research, 12: 149S–150S. doi: 10.1038/oby.2004.281
- Issue published online: 6 SEP 2012
- Article first published online: 6 SEP 2012
- 1National Center for Health Statistics. (2004) Prevalence of Overweight among Children and Adolescents: United States, 1999-2000. http:www.cdc.govnchsproductspubspubdhestatsoverwght99.htmTable201 (Accessed June 11).
- 2National Center for Chronic Disease Prevention and Health Promotion. (2004) U.S. Obesity Trends 1985 to 2002. http:www.cdc.govnccdphpdnpaobesitytrendmapsindex.htm (Accessed June 11).